PF-06939926
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PF-06939926, covering 2024-09-20 to 2025-06-08. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy [Phase 3]